Three nationally recognized physicians — **Dr. Philip Drum**, **Dr. Ken Finn**, and **Dr. Karen Randall** — testified before the DEA to oppose moving marijuana from **Schedule I to Schedule III**. Their expert witness statements reveal the medical, scientific, and public‑health dangers of rescheduling cannabis. **Dr. Philip Drum** explained how the **Controlled Substances Act** works and why marijuana has *never* met the FDA’s requirement for “accepted medical use.” He cited more than **9,500 federally funded studies** and **$4.2 billion** in taxpayer‑funded research — none of which resulted in a single FDA‑approved indication. He also exposed the false claim that cannabis “cannot be researched,” showing marijuana is one of the most heavily studied substances in U.S. history. **Dr. Ken Finn**, a pain physician with 30 years of experience, described how marijuana consistently **fails to treat pain**, despite widespread belief. He revealed that the DEA’s own internal study — the one being used to justify rescheduling — is **secretive, flawed, and cannot be reproduced**. He also highlighted that fewer than **5% of physicians** in legal‑cannabis states have ever recommended marijuana, with a small number of doctors issuing the majority of recommendations — a pattern reminiscent of the opioid pill‑mill era. **Dr. Karen Randall**, an emergency physician and pediatric specialist, delivered the most alarming warnings. She described the explosion of **pediatric cannabis exposure**, the rise of **cannabis hyperemesis syndrome**, and the growing number of children experiencing **cannabis‑induced psychosis** — including cases as young as **seven years old**. She shared a devastating case of a **13‑year‑old girl trading sex for marijuana**, illustrating the real‑world consequences of liberalized drug messaging and the false belief that cannabis is “safe” or “healthy.” Together, these expert witnesses argue that rescheduling marijuana to Schedule III will: - Mislead the public into believing cannabis is safe - Increase youth access and exposure - Expand diversion - Reduce regulatory oversight - Ignore decades of medical evidence - Create long‑term harm to developing brains This is **Part 1** of their testimony before the DEA. Part 2 will be released shortly.

Also watch